Get the latest news, insights, and market updates on GDRX (GoodRx Holdings, Inc.). Explore the news page 5 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
How the Story Around GoodRx Is Shifting as Analyst Sentiment and Partnerships Evolve
The consensus analyst price target for GoodRx Holdings has been revised downward, moving from $5.37 to $5.09 per share. This modest reduction reflects shifting perspectives among analysts regarding the company’s growth prospects. Ongoing industry headwinds are creating near-term uncertainty, although there are areas of optimism over strategic partnerships. Stay tuned to discover how you can track these evolving expectations and keep pace with the GoodRx narrative as it unfolds. Stay updated... Nov 20, 2025 - $GDRX
3 Small-Cap Stocks That Fall Short
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors. Nov 19, 2025 - $GDRX
GoodRx Launches New $39 Per Month Weight Loss Telemedicine Subscription, Unveils Industry-Leading Introductory Cash Price of $199 Per Month for Ozempic® and Wegovy®
SANTA MONICA, Calif., November 17, 2025--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced two major initiatives to make FDA-approved GLP-1 medications more widely available. First, the launch of GoodRx for Weight Loss, a telemedicine subscription that connects consumers to licensed healthcare providers for affordable weight management treatment. Second, in partnership with Novo Nordisk, a new introductory cash price of $199 per month for Ozempic® (s Nov 17, 2025 - $GDRX
5 Revealing Analyst Questions From GoodRx’s Q3 Earnings Call
GoodRx’s third quarter results were met with a moderate positive market response, as the company’s revenue modestly exceeded Wall Street expectations despite being flat year-over-year. Management highlighted a mix of strategic wins, such as expanded partnerships with pharmaceutical manufacturers and new pharmacy integrations, as key drivers. CEO Wendy Barnes cited the launch of direct-to-consumer pricing programs with major brands like Novo Nordisk and Amgen, as well as the rollout of the RxSmar Nov 11, 2025 - $GDRX
3 Value Stocks We Find Risky
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues. Nov 10, 2025 - $GDRX
A Look at GoodRx (GDRX) Valuation Following a 27% One-Month Share Price Decline
GoodRx Holdings (GDRX) shares have slipped about 27% over the past month, drawing investor attention to recent performance trends. The company’s ongoing path sparks questions about how current dynamics may influence its value moving forward. See our latest analysis for GoodRx Holdings. The 27% dip in GoodRx's share price over the past month marks a sharp acceleration in its recent downward momentum and stretches the year-to-date share price decline to nearly 32%. While the company has posted... Nov 9, 2025 - $GDRX
Goldman Sachs Raises GoodRx (GDRX) Price Target, Keeps Neutral Rating
GoodRx Holdings, Inc. (NASDAQ:GDRX) is one of the 12 Best American Penny Stocks to Buy Right Now. On November 6, Goldman Sachs increased its price target on GoodRx Holdings, Inc. (NASDAQ:GDRX) from $3.75 to $4 and kept a Neutral rating. This decision came after the company reported its results for the third quarter of 2025. […] Nov 8, 2025 - $GDRX
3 Low-Volatility Stocks with Open Questions
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. Nov 6, 2025 - $GDRX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple